Condition: Solid Tumor · Sponsor: Teligene US
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
This description comes directly from the study's public registry record.
Xiaoyang Xia · 8053009373 · xiaoyang.xia@teligene.com
Dawei Zhang · 8053001019 · david.zhang@teligene.com
Always discuss trial participation with your own doctor first.
| Adventist Health Glendale | Glendale, California, United States | Recruiting |
| Texas Oncology | Dallas, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University School and Hospital of Stomatology | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Harbin medical university cancer hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06010342